Abstract: An OLED including an anode, a cathode, and an organic layer between the anode and the cathode, where the organic layer includes a compound having the formula [LA]3-nIr[LB]n is disclosed.

Abstract: Provided is a new composition of matter for phosphorescent emitters containing a chelating ligand comprised of a fused heterocyclic structure containing boron. The disclosed ligands form two bonds to the metal forming a 6-membered chelate and can be further substituted to form tridentate or tetradentate ligands.

Abstract: A compound having a structure of Formula I In Formula I, M is Pd or Pt; each of X1 to X12 is independently C or N; ring A is a 5-membered or 6-membered ring; K1 and K2 are selected from a direct bond, O, S, and NR; L1 is an organic linker; Y1 is selected from O, S, BR, PR, Se and NRY; each R, RY, RA, RB, RC, and RD is hydrogen or a substituent; and any two substituents can be joined or fused to form a ring. Further provided are OLEDs and related consumer products that utilize these compounds.

Abstract: Provided are organometallic compounds comprising two moieties A and B which are each independently a monocyclic ring or a polycyclic fused ring structure, wherein the monocyclic ring or each ring of the polycyclic fused ring structure is independently a 5-membered to 10-membered carbocyclic or heterocyclic ring which are linked by a direct bond and which are further bridged by a linker comprising two groups which are each independently selected from the group consisting of O, S, Se, NR, BR, BRR?, PR, CR, C?O, C?NR, C?CRR?, C?S, CRR?, SO, SO2, P(O)R, SiRR?, and GeRR?. Also provided are formulations comprising these organometallic compounds. Further provided are organic light emitting devices (OLEDs) and related consumer products that utilize these organometallic compounds.

Abstract: A compound comprising a first bidentate ligand LA, wherein LA comprises a structure of Formula I; wherein Z is selected from the group consisting of O, S, NR, BR, CRKRL, C?CRKRL, SiRKRL, —CRKRLCRMRN—, —SiRKRLSiRMRN—, —CRKRLO—, —SiRKRLO—, and —CRK?CRL—; wherein ring A, ring B, and ring C are each independently a 5-membered carbocyclic ring, 5-membered heterocyclic ring, 6-membered carbocyclic ring or 6-membered heterocyclic ring; wherein LA is coordinated to a metal M forming a 5-membered chelate ring; wherein M is selected from the group consisting of Ir, Pt, Pd, Ru, Rh, Os, Re, Cu, Ag, and Au; wherein RA, RB, and RC each represent mono to the maximum allowable substitution, or no substitution; wherein each R, RK, RL, RM, RN, RA, RB, and RC is independently a hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, germyl, boryl, selenyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, a

Abstract: A compound comprising a first ligand LA comprising a structure of Formula I, is provided. In Formula I, each of moiety A and moiety B is a monocyclic ring or a polycyclic fused ring system; each of X1 to X4 and Z1 to Z4 is C or N; at least one of X1 to X4 is N; each of K1 and K2 is a direct bond or a linker; Y is a linker; each R, R?, R?, R?, RA, RB, and RC is hydrogen or a substituent; LA is coordinated to a metal M; and at least one of five conditions related to X1 to X4 and/or RC is met. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A heteroleptic compound of formula Ir(LA)m(LB)n(LC)p is provided wherein LA has a structure of Formula IA, or Formula IB, LB has a structure of Formula II, and LC is a bidentate ligand; and wherein m is 1 or 2; n is 1 or 2; and p is 0 or 1; and m+n+p=3 In Formulae I and II, moieties A and D are heterocyclic ring or a polycyclic ring system; each of X1 to X12 is C or N; Ring B is connected to moiety A by a C; at least one of X9 to X12 is N; Y is a linking group that forms a 5-membered ring; each R, R?, R?, RA, RB, RC, RD, and RE is hydrogen or a General Substituent as defined herein; LA forms a 5-membered chelate ring with Ir. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: Provided are a compound comprising a ligand LA of Formula I that are useful as emitters in organic light emitting devices.

Abstract: A compound having the formula Ir(LA)n(LB)3-n, having the structure of Formula I is provided. In the structure of Formula I, each of A1 through A8 is independently carbon or nitrogen; at least one of A1 through A8 is nitrogen; ring B is bonded to ring A through a C—C bond; the iridium is bonded to ring A through an Ir—C bond; X is O, S, or Se; each of R1 through R5 are independently selected from a variety of substituents, which may be linked for form a ring; n is an integer from 1 to 3; and at least one R2 adjacent to ring C is not hydrogen. Formulations and devices, such as OLEDs, that include the first compound are also provided.

Abstract: A compound having a metal coordination complex structure, where the compound is capable of functioning as a phosphorescent emitter in an organic light emitting device at room temperature is disclosed. The compound has a first ligand coordinated to a metal. The free-state of the first ligand has a first triplet energy T1 of EL at 77K, while the compound has a first triplet energy T1 of E at 77K, and the difference in energy (?E) between E and EL is ?250 meV. The compound has a triplet emission spectrum with a FWHM value of no more than 45 nm. Organic light emitting devices, consumer products, and formulations containing the compounds are also disclosed.

Abstract: Provided are organometallic compounds including a ligand LA of Formula I: Also provided are formulations including these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

Abstract: A compound of formula Ir(LA)x(LB)y(LC)z, where x and y are 1 or 2; z is 0 or 1; and x+y+z=3. In the compound, LA comprises Formula I, ligand LB comprises Formula II, and ligand LC is a bidentate ligand. In Formulas I and II, moiety A is a monocyclic ring or a polycyclic fused ring system; each of X1 to X14 is C or N; Y is a linking group; each R1-R2, R, R?, and RA-RE is hydrogen or a General Substituent defined herein; at least one of R1 and R2 is a tertiary alkyl group; and (1) at least one pair of RB or RC substituents are joined or fused to form a ring, or (2) at least one RC or RB comprises an electron-withdrawing group other than nitrile, or (3) X11 is N, R1 is a tertiary alkyl group. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound comprising a first ligand LA of Formula I, is provided. In Formula I, moiety A is a 5-membered or 6-membered ring; moiety B is a fused ring structure comprising at least four rings; K is a direct bond, O, or S; each of Z1 and Z2 is independently C or N; each RA and RB is independently hydrogen or a General Substituent; at least one RB comprises a cyclic group or an electron-withdrawing group; LA is coordinated to a metal M that has an atomic mass of at least 40 and is optionally coordinated to other ligands; and the ligand LA is optionally linked with other ligands. Formulations, OLEDs, and consumer products including the compound are also provided.

Abstract: A compound comprising a first ligand LA of Formula I, is provided. In Formula I, moiety A is a carbocyclic or heterocyclic ring; Q is C, N, B, or Si; each of X1 to X5 is C or N; Y is a linking group; K is a direct bond or a linking group; each R, R?, R?, R?, R?, RA, RB, and RC is hydrogen or a General Substituent defined herein; no two RA are joined; and at least one RA, RB, or RC includes a silyl group or a germyl group. Formulations, OLEDs, and consumer products containing the same are also provided.

Abstract: A compound of Formula Ir(LA)x(LB)y(LC)z is provided. In Formula Ir(LA)x(LB)y(LC)z, x, Y, and z are non-negative integers; x+y+z=3; LA has a structure of Formula I, LB and LC are bidentate ligands; moiety A is a monocyclic ring or a polycyclic fused ring system; ring C is a 5- or 6-membered heterocyclic ring; each of Z, Z1, X1 to X6 is independently C or N; each of X and Y is a linker that is one-atom in length; each independently represents a single bond or a double bond; each R, R?, RA, RB, and RC is hydrogen or a General Substituent defined herein. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound of formula Ir(LA)x(LB)y(LC)z, where x and y are 1 or 2; z is 0 or 1; and x+y+z=3. In the compound, LA comprises Formula I, ligand LB comprises Formula II, and ligand LC is a bidentate ligand. In Formulas I and II, moiety A is a monocyclic ring or a polycyclic fused ring system; each of X1 to X14 is C or N; Y is a linking group; each R1-R2, R, R?, and RA-RE is hydrogen or a General Substituent defined herein; at least one of R1 and R2 is a tertiary alkyl group; and (1) at least one pair of RB or RC substituents are joined or fused to form a ring, or (2) at least one RC or RB comprises an electron-withdrawing group other than nitrile, or (3) X11 is N, R1 is a tertiary alkyl group. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound comprising a first ligand LA of Formula I, is provided. In Formula I, each of X1 to X6 is C or N; K is a direct bond or a linker; each of L1 and L2 is a linker; each R, R?, R?, R?, RA, and RB is hydrogen or a General Substituent defined herein; two RB are joined to form a ring; LA is coordinated to a metal M. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound of Ir(LA)m(LB)3-m, having a structure of is provided. In Formula I or Formula II, moieties A and B are each either a monocyclic ring or a polycyclic fused ring system; X1 to X8 and Z1 to Z4 are C or N; Y is a single atom linker, which can be substituted; each R1, R2, R3, R4, and R5 is hydrogen or a General Substituent; m is 1 or 2; at least one of R1, R2, and R3 comprises at least one first electron-withdrawing group; and at least one of R4 and R5 comprises at least one second electron-withdrawing group. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound having a first ligand LA including a structure of Formula I: In Formula I, ring A is 5-membered heterocyclic ring; each of Z1, Z2, and X1 to X5 is C or N; Y is a linking group; K is a direct bond or a linking group; RZ is a General Substituent defined herein; each other substituent is hydrogen or a General Substituent defined herein; and (1) two RC substituents are joined together to form a ring, or (2) the compound comprises an electron-withdrawing group. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: Provided are a compound having a metal M and a first ligand LA comprising the structure of where the compound is capable of functioning as a phosphorescent emitter in an organic light emitting device at room temperature.